Maurel M, Howard J, Kissling E, Pozo F, Pérez-Gime. Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024. Euro Surveill. 2024 Feb;29(8)
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), respectively.
See Also:
Latest articles in those days:
- Pathogenicity of Highly Pathogenic Avian Influenza A/H5Nx Viruses in Avian and Murine Models 5 hours ago
- [preprint]No Evidence of Anti-influenza Nucleoprotein Antibodies in Retail Milk from Across Canada (April - July 2024) 17 hours ago
- Spatial risk modelling of highly pathogenic avian influenza in France: Fattening duck farm activity matters 18 hours ago
- Coordinated One Health investigation and management of outbreaks in humans and animals caused by zoonotic avian influenza viruses 2 days ago
- Assessing the Use of Different Surveillance Components to Detect Highly Pathogenic Avian Influenza Outbreaks in Poultry in the Netherlands in Low- and High-Risk Years 2 days ago
[Go Top] [Close Window]
